CLN3 and Blindness: Ultimately, if RPE dysfunction and POS phagocytosis defect are central to photoreceptor cell loss and retinal degeneration in CLN3 disease and CLN3-associated non-syndromic retinal degeneration, RPE cells may be a crucial gene therapy target for these blinding disorders.